BPC-157 (10 mg Vial) Dosage Protocol

BPC-157 (10 mg)

Dosage Protocol

At a Glance

BPC-157 10mg Vial

BPC-157 (Body Protection Compound-157) is a 15-amino acid synthetic peptide derived from human gastric juice proteins that accelerates localised tissue repair via FAK-paxillin pathway activation, VEGF upregulation, and NO-pathway normalisation.[1] The 10 mg vial provides double the peptide of a standard 5 mg vial, offering greater convenience for longer cycles or higher-dose protocols.

  • Reconstitute: Add 3.0 mL bacteriostatic water → 3.33 mg/mL concentration.
  • Standard dose: 250–500 mcg once or twice daily (subcutaneous).
  • Easy measuring: At 3.33 mg/mL on a U-100 syringe, 1 unit = 0.01 mL ≈ 33.3 mcg. A 500 mcg dose = 15 units / 0.15 mL.
  • Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks.

Overview

  • Goal: Accelerate localised tissue repair via FAK-paxillin pathway, VEGF upregulation, NO-pathway normalisation, and gut mucosal protection.[1]
  • Schedule: Daily subcutaneous injection for 8–12 weeks; reassess before extending.
  • Dose range: 250–750 mcg once or twice daily.
  • Reconstitution: 3.0 mL BAC water per 10 mg vial → 3.33 mg/mL.
  • Injection site: Near injury site (subcutaneous) for musculoskeletal; abdomen for gut applications.

What You’ll Need

Plan based on an 8-week cycle at 500 mcg once daily (56 injections, 28 mg total).

  • BPC-157 Vials (10 mg each): 28 mg needed ÷ 10 mg per vial → 3 vials.
  • Insulin Syringes (U-100, 0.3 mL / 30-unit): 56 injections → 56 syringes.
  • Bacteriostatic Water (10 mL bottles): 3.0 mL per vial → 1 × 10 mL bottle.
  • Alcohol Swabs: 2 per injection → 112 swabs per 8-week cycle.

How to Reconstitute

  1. Allow frozen lyophilised vial to reach room temperature (10–15 minutes).
  2. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the inner vial wall to avoid foaming.
  4. Gently swirl until fully dissolved — do not shake. Solution should be clear and colourless.
  5. Label with reconstitution date; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Dosing Schedule

Week Daily Dose Units (U-100) Volume Frequency
1 250 mcg 7.5 units 0.075 mL Once daily
2–4 500 mcg 15 units 0.15 mL Once or twice daily
5–8 750 mcg 22.5 units 0.225 mL Once or twice daily

Start at 250 mcg once daily for the first week to assess tolerance, then increase to 500 mcg. For acute musculoskeletal injuries, injecting near (not into) the injury site enhances local FAK-paxillin activity. At 500 mcg once daily, one 10 mg vial lasts about 20 days.

Protocol Details

  • Starting dose: 250 mcg (7.5 units / 0.075 mL) once daily for Days 1–5.[1]
  • Standard dose: 500 mcg (15 units / 0.15 mL) once or twice daily from Day 6+.
  • Advanced dose: 750 mcg (22.5 units / 0.225 mL) twice daily for acute injuries.
  • Cycle: 8–12 weeks continuous; may extend to 16 weeks if well tolerated.
  • For acute injuries: Inject subcutaneously within 2–5 cm of the injured tissue when safely accessible.

Storage

  • Lyophilised: Store at −20 °C (−4 °F); protect from moisture and light.
  • Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
  • Appearance: Clear, colourless solution. Discard if cloudy, coloured, or particulate.

How BPC-157 Works

BPC-157 is a 15-amino acid synthetic peptide (GEPPPGKPADDAGLV) derived from gastric juice proteins. Its primary repair mechanism involves activation of the FAK-paxillin pathway in tendon fibroblasts, fibroblasts, and endothelial cells, driving cell outgrowth and migration into injured tissue.[1]

Concurrently, BPC-157 upregulates VEGF receptor expression to stimulate new blood vessel formation, and normalises the nitric oxide (NO) pathway to restore vascular function at the injury site. It reduces prostaglandin E2 production, blunting inflammatory pain and swelling during the early repair phase. In the gut, it protects the mucosal lining, promotes epithelial repair, and counteracts NSAID- and corticosteroid-induced damage — which is why it has been studied in models of inflammatory bowel disease and leaky gut.[1]

Good to Know

  • For acute injuries, injecting near the injury site (not into muscle or joint) maximises BPC-157’s local FAK-paxillin and VEGF effects.
  • WADA-prohibited (Category S2) — competitive athletes subject to anti-doping rules must not use BPC-157.
  • BPC-157 is often combined with TB-500 for complementary local + systemic repair. See the Wolverine Stack Protocol.
  • The 10 mg vial lasts approximately twice as long as a 5 mg vial, reducing reconstitution frequency and offering better value for multi-week cycles.
  • Rotate injection sites daily; record site and dose to track local reactions.
  • Tendon and muscle repair: Extensive preclinical evidence across 35+ studies; benefit in tendon, muscle, bone, and cartilage repair.[1]
  • Gut protection: Reduces NSAID-induced gut damage; promotes mucosal healing in colitis models.
  • Safety profile: No significant adverse effects in preclinical studies at standard research doses; human safety data limited to case reports and one small pilot study.
  • WADA status: Prohibited in- and out-of-competition (S2: Non-Approved Peptide Hormones).
  • Synergy with TB-500: Best combined as the Wolverine Stack for comprehensive local + systemic tissue repair. See What Is the Wolverine Stack?

Tips for Best Results

  • Maintain adequate dietary protein (1.2–1.6 g/kg) to provide amino acids for collagen and tissue synthesis.
  • Avoid NSAIDs during a BPC-157 protocol — they can blunt the NO-pathway and VEGF signalling that BPC-157 potentiates.
  • Gentle mobilisation (range-of-motion exercises) within pain-free range supports capillary ingrowth and fibroblast recruitment.
  • Adequate sleep (7–9 hours) supports anabolic repair processes.

Injection Tips

  • Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully before proceeding.
  • Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose precisely.
  • Pinch a fold of skin and insert the needle at 45° into subcutaneous fat (90° is acceptable with a short needle into a well-pinched fold).
  • Inject slowly over 2–3 seconds; do not aspirate. Withdraw the needle, apply gentle pressure, and do not rub the site.
  • Rotate injection sites (abdomen, thighs, upper arms) and dispose of each syringe in a sharps container immediately after use.

References


  • Gwyer D et al. — PMC (2025) — Orthopaedic Review of BPC-157
    — Comprehensive review of 35 preclinical studies and 1 human pilot trial covering tendon, muscle, bone, and cartilage repair; FAK-paxillin mechanism
    View Source

  • Sikiric P et al. — Journal of Physiology and Pharmacology (multiple)
    — BPC-157 FAK-paxillin pathway activation in tendon fibroblasts; NO-pathway and VEGF upregulation mechanisms
    View Source

  • Bachem Peptide Technical Guide
    — Handling and Storage Guidelines for Peptides (lyophilised and reconstituted forms)
    View Source

  • CDC — General Best Practice Guidelines for Immunization
    — Subcutaneous injection technique, angle, and site rotation guidance
    View Source

Important Note

This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. This peptide is not approved for human therapeutic use. For research use only.

Looking for research-grade BPC-157 (10 mg)? Our sponsor White Market Peptides carries BPC-157 (10 mg) with third-party purity testing. Use code PEPDOSE for 10% off + free 2-day shipping over $200.